Most cited papers in Cutaneous Melanoma Detection and Management
What are the most cited papers in Cutaneous Melanoma Detection and Management?
The most cited paper in Cutaneous Melanoma Detection and Management is "Dermatologist-level classification of skin cancer with deep neural networks" (Andre Esteva, Brett Kuprel, Roberto A. Novoa et al., 2017), with 14,423 citations. Next come "Tumor Angiogenesis: Therapeutic Implications" (10,238) and "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation" (7,801).
Showing 50 of 100 papers. Every paper with more than 973 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Dermatologist-level classification of skin cancer with deep neural networks Andre Esteva, Brett Kuprel, Roberto A. Novoa et al. · Nature | 25 Jan 2017 | 14,423 |
| 2 | Tumor Angiogenesis: Therapeutic Implications Louis M. Sherwood, Edith E. Parris, Judah Folkman · New England Journal of Medicine | 18 Nov 1971 | 10,238 |
| 3 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman et al. · New England Journal of Medicine | 5 Jun 2011 | 7,801 |
| 4 | Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert et al. · New England Journal of Medicine | 19 Apr 2015 | 5,968 |
| 5 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok et al. · New England Journal of Medicine | 11 Sep 2017 | 5,453 |
| 6 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation Caroline Robert et al. · New England Journal of Medicine | 16 Nov 2014 | 5,431 |
| 7 | Final Version of 2009 AJCC Melanoma Staging and Classification Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology | 16 Nov 2009 | 4,621 |
| 8 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert et al. · New England Journal of Medicine | 5 Jun 2011 | 4,523 |
| 9 | Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma Donald L. Morton · Archives of Surgery | Apr 1992 | 4,420 |
| 10 | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Keith T. Flaherty, Igor J. Puzanov, Kevin B. Kim et al. · New England Journal of Medicine | 25 Aug 2010 | 3,581 |
| 11 | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid et al. · New England Journal of Medicine | 2 Jun 2013 | 3,425 |
| 12 | Genomic Classification of Cutaneous Melanoma Rehan Akbani et al. · Cell | Jun 2015 | 3,302 |
| 13 | Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma Jesse Meir Zaretsky et al. · New England Journal of Medicine | 13 Jul 2016 | 3,284 |
| 14 | Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Jedd D. Wolchok, Axel Hoos, Steven J O'Day et al. · Clinical Cancer Research | 24 Nov 2009 | 3,279 |
| 15 | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Axel Hauschild et al. · The Lancet | 25 Jun 2012 | 3,009 |
| 16 | Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer Armando E. Giuliano, Daniel M. Kirgan, Julia Guenther et al. · Annals of Surgery | Sep 1994 | 2,923 |
| 17 | Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty et al. · New England Journal of Medicine | 30 Sep 2012 | 2,838 |
| 18 | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Michael Andrew Postow et al. · New England Journal of Medicine | 20 Apr 2015 | 2,804 |
| 19 | Distinct Sets of Genetic Alterations in Melanoma John A. Curtin, Jane Fridlyand, Toshiro Kageshita et al. · New England Journal of Medicine | 16 Nov 2005 | 2,732 |
| 20 | Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Caroline Robert et al. · New England Journal of Medicine | 16 Nov 2014 | 2,718 |
| 21 | Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma Charles M. Balch, Antonio Carlos Buzaid, Seng‐Jaw Soong et al. · Journal of Clinical Oncology | 15 Aug 2001 | 2,660 |
| 22 | Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma Alexander Breslow · Annals of Surgery | Nov 1970 | 2,452 |
| 23 | Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System Charles M. Balch, Seng‐Jaw Soong, Jeffrey E. Gershenwald et al. · Journal of Clinical Oncology | 15 Aug 2001 | 2,418 |
| 24 | Mass customization: The new frontier in business competition B. Joseph Pine · Journal of Manufacturing Systems | 1999 | 2,331 |
| 25 | Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess et al. · CA A Cancer Journal for Clinicians | 13 Oct 2017 | 2,317 |
| 26 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber et al. · New England Journal of Medicine | 10 Sep 2017 | 2,249 |
| 27 | Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Suzanne Louise Topalian et al. · Journal of Clinical Oncology | 3 Mar 2014 | 2,232 |
| 28 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Ramin Nazarian, Hubing Shi, Qi Wang et al. · Nature | 24 Nov 2010 | 2,203 |
| 29 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Keith T. Flaherty et al. · New England Journal of Medicine | 14 Jun 2012 | 2,179 |
| 30 | Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib Jeffrey Alan Sosman et al. · New England Journal of Medicine | 22 Feb 2012 | 2,170 |
| 31 | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Dirk Schadendorf, Frank Stephen Hodi, Caroline Robert et al. · Journal of Clinical Oncology | 9 Feb 2015 | 2,157 |
| 32 | Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J M Kirkwood, M H Strawderman, Marc S. Ernstoff et al. · Journal of Clinical Oncology | 1996 | 2,110 |
| 33 | High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 Michael B. Atkins, Michael T. Lotze, Janice P. Dutcher et al. · Journal of Clinical Oncology | Jul 1999 | 2,055 |
| 34 | A systematic review of worldwide incidence of nonmelanoma skin cancer Andrew Lomas, Jo Leonardi‐Bee, Fiona J Bath-Hextall · British Journal of Dermatology | 17 Jan 2012 | 1,956 |
| 35 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Alexander M.M. Eggermont et al. · New England Journal of Medicine | 15 Apr 2018 | 1,906 |
| 36 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma Hussein A. Tawbi et al. · New England Journal of Medicine | 5 Jan 2022 | 1,887 |
| 37 | Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012 Howard W. Rogers, Martin A. Weinstock, Steven R. Feldman et al. · JAMA Dermatology | 30 Apr 2015 | 1,846 |
| 38 | Sentinel-Node Biopsy or Nodal Observation in Melanoma Donald L. Morton, John F. Thompson, Alistair J. Cochran et al. · New England Journal of Medicine | 27 Sep 2006 | 1,840 |
| 39 | The epidemiology of UV induced skin cancer Bruce Konrad Armstrong, Anne Kricker · Journal of Photochemistry and Photobiology B Biology | Oct 2001 | 1,834 |
| 40 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert et al. · The Lancet | 14 Jul 2014 | 1,779 |
| 41 | Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe David N. Krag, Donald L. Weaver, James C. Alex et al. · Surgical Oncology | Dec 1993 | 1,689 |
| 42 | The National Cancer Data Base report on cutaneous and noncutaneous melanoma Alfred E. Chang, Lucy Hynds Karnell, Herman R. Menck · Cancer | 15 Oct 1998 | 1,676 |
| 43 | Somatic Activation of KIT in Distinct Subtypes of Melanoma John A. Curtin, Klaus Johannes BUSAM, Daniel Pinkel et al. · Journal of Clinical Oncology | 14 Aug 2006 | 1,620 |
| 44 | Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists Holger Andreas Haenssle et al. · Annals of Oncology | 4 May 2018 | 1,612 |
| 45 | Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma Leo J. Schouten, Joost Rutten, Hans A. M. Huveneers et al. · Cancer | 14 May 2002 | 1,604 |
| 46 | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Antoni Ribas et al. · The Lancet Oncology | 24 Jun 2015 | 1,581 |
| 47 | Whole-genome landscapes of major melanoma subtypes Nicholas K. Hayward et al. · Nature | May 2017 | 1,548 |
| 48 | Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040 Melina Arnold, Deependra Singh, Mathieu Laversanne et al. · JAMA Dermatology | 30 Mar 2022 | 1,520 |
| 49 | Melanoma Dirk Schadendorf, Alexander C. J. van Akkooi, Carola Berking et al. · The Lancet | Sep 2018 | 1,518 |
| 50 | Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma Georgina Venetia Long et al. · New England Journal of Medicine | 10 Sep 2017 | 1,501 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.